The biologics CDMO secondary packaging market will touch USD 3,622.6 million by 2030, powering at a rate of 8.7% by the end of this decade. This growth is credited to the snowballing drug production, the increasing pharma industry, and the growing prevalence of numerous diseases, such as chronic ailments, infectious ailments, and genetic diseases.
Boxes were the largest category in the industry, with about USD 1 billion revenue, in 2021, and they will continue dominations in the years as well.
Boxes are designed explicitly for the transport of biological products, such as frozen and controlled ambient biologics. They also provide the perfect balance between temperature control and payloads.
North America had the largest revenue share, more than 40%, in the biologics CDMO secondary packaging market. This is because of the increasing outsourcing of drug research and development and production activities by major biopharma players.
Numerous companies wish to team up with competent packing providers providing non-conventional packing solutions and have the vital capabilities to formulate exclusive packing designs in a time and cost-effective manner.
Instead, the APAC will have the fastest growth in the years to come. This growth has a lot to do with the increasing prevalence of chronic ailments, the growing emphasis of businesses on contract manufacturing, and key players are keenly interested in facility developments in the Asia Pacific region.
Furthermore, the growth of the European region will be moderate in nature in the years to come. This can be mainly as a result of the increasing requirement for biologic products, for instance vaccines, driving the research and development spending of the pharma companies.
Due to the increased production of drugs all over the world, the demand for biologics CDMO secondary packaging is on the rise, and this trend will continue in the years to come as well.